Avantor granted Executive Vice President, Chief Legal and Compliance Officer and Secretary Claudius Sokenu 62,305 restricted stock units on October 31, 2026, vesting in equal installments over the first three anniversaries.
AVTR · Avantor, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Avantor returned to organic growth in Q3, posting 5.2% revenue growth and $0.22 adjusted EPS. It raised 2026 organic revenue growth guidance to 0.75 to 1.25%, adjusted EPS to $0.81 to $0.83, and free cash flow to $525 to $550 million.
Avantor reported third-quarter net sales of $1,698.3 million, up 4.6%, and net income of $203.4 million, while Adjusted EBITDA declined $11.0 million. The VWR Distribution reporting unit faced potential goodwill impairment.
Avantor's third-quarter net sales were $1,698.3 million, up 4.6% and 5.2% organically. It raised fiscal 2026 organic revenue growth guidance to +0.75% to +1.25% and free cash flow guidance to $525M to $550M.
Avantor, Inc. appointed Todd Garner Executive Vice President and Chief Financial Officer effective September 21, 2026, with $700,000 annual base salary, 80% target bonus, $150,000 signing bonus, and a targeted $1,500,000 initial equity grant.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Jul 29, 2026TL;DR. Avantor raised its full-year 2026 organic revenue growth guidance to -0.5% to +0.5% and adjusted EPS guidance to $0.80–$0.83 after Q2 results beat expectations, with VWR returning to positive organic growth and the company repaying $112 million of debt while maintaining a 3.3x adjusted net leverage ratio. However, adjusted EBITDA and segment margins still declined year-over-year on mix and inflationary pressures, and FX is expected to be a headwind in the second half.
- + Raised full-year 2026 organic revenue growth guidance to -0.5% to +0.5% (from -2.5% to -0.5%)
- + Raised full-year 2026 adjusted EPS guidance to $0.80–$0.83 (from $0.77–$0.83)
- + VWR Distribution & Services returned to positive organic revenue growth of 1.7% in Q2
- + Q2 free cash flow of $142.8 million (or $152 million excluding cash restructuring costs) ahead of expectations
- − Total adjusted EBITDA margin declined to 15.0% in Q2 from 16.6% year-over-year
- − FX expected to be a headwind to reported revenue in the second half of 2026
- − GAAP net income fell to $38.1 million in Q2 from $64.7 million in Q2 2025
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $254.3M | the three months ended June 30, 2026 filing | — |
| Adjusted EBITDA margin non-GAAP | 15% | three months ended June 30, 2026 filing | — |
| Adjusted Operating Income non-GAAP | 225.1M | Three months ended June 30, 2026 filing | — |
| Adjusted Operating Income - Bioscience & Medtech Products non-GAAP | $117.6M | three months ended June 30, 2026 filing | — |
| Adjusted Operating Income - Corporate non-GAAP | -$18.9M | three months ended June 30, 2026 filing | — |
| Adjusted Operating Income - VWR Distribution & Services non-GAAP | $126.4M | three months ended June 30, 2026 filing | — |
| Adjusted Operating Income margin non-GAAP | 13.3% | three months ended June 30, 2026 filing | — |
| Bioscience & Medtech Products depreciation and amortization | $49.2M | Three months ended June 30, 2026 filing | — |
| Total depreciation and amortization | $105.6M | Three months ended June 30, 2026 filing | — |
| VWR Distribution & Services depreciation and amortization | $56.4M | Three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AVTR
this stock
Avantor, Inc.
|
$10.38B | +33.7% | -3.4% | 30.6 | 4.0% |
|
ISRG
Intuitive Surgical Inc
|
$151.74B | -22.7% | +20.5% | 53.1 | 2.0% |
|
BDX
Becton Dickinson & Co
|
$58.96B | — | +8.2% | 95.8 | 3.0% |
|
MDLN
Medline Inc.
|
$51.52B | -6.7% | +11.5% | — | 2.9% |
|
ALC
Alcon Inc
|
$35.38B | -6.6% | +10.5% | — | 3.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 3, 2026
- This year
- 21
Avantor granted Executive Vice President, Chief Legal and Compliance Officer and Secretary Claudius Sokenu 62,305 restricted stock units on October 31, 2026, vesting in equal installments over the first three anniversaries.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AVTR | -3.7% | -6.0% | +82.4% | -4.6% | +33.7% |
| SPY | -1.7% | -3.5% | -1.4% | -2.1% | +8.5% |
| vs SPY | -2.0% | -2.5% | +83.8% | -2.5% | +25.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.